Evaluation of a Resiliency Intervention for Siblings of Children With Autism Spectrum Disorder (ASD) (SibChat)
4 de abril de 2022 actualizado por: Karen Kuhlthau, Massachusetts General Hospital
The proposed research has the following objectives:
Based off findings from the "Development of a Resiliency Program for Siblings of Children with Autism Spectrum Disorder" qualitative focus group study (protocol 2019P002284), the aim is to determine the feasibility and acceptability, of an 8-session Relaxation Response Resiliency (SibChat) program for siblings of children with ASD.
We primarily aim to test the preliminary effectiveness of a pilot waitlist controlled trial on improving resiliency and stress coping, This will be assessed by comparing Baseline-3 mo. scores on primary and secondary outcome measures between the Immediate and Waitlist control groups.
Among participants randomized to both conditions, we secondarily aim to investigate the extent of pre-post changes in primary and secondary outcomes. Among immediate condition group only, we also aim to assess whether end-of-treatment (3 mo. post enrollment) improvements will be sustained at 6-mo. post enrollment.
Descripción general del estudio
Estado
Terminado
Condiciones
Intervención / Tratamiento
Descripción detallada
This intervention will be a modified version of Dr. Elyse Park's evidence-based 8-week multimodal treatment which is designed to promote adaptation to stress and promotion of resiliency.
The program is an 8 session, 1 hour a week multi modal intervention that incorporates relaxation techniques, stress awareness discussion, and adaptive strategies for coping with stress.
This study will refine an 8-session group virtual-delivered resiliency treatment program consisting of 8 virtual group 1-1 ½ hour sessions.
The goal of this study would be to advance our ultimate objective to implement a national sibling resiliency program.
Tipo de estudio
Intervencionista
Inscripción (Actual)
44
Fase
- No aplica
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Ubicaciones de estudio
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02215
- Massachusetts General Hospital
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
14 años a 17 años (Niño)
Acepta Voluntarios Saludables
No
Géneros elegibles para el estudio
Todos
Descripción
Inclusion Criteria:
- Age 14-17 years (inclusive of ages 14 and 17)
- Being the sibling of at least one individual with ASD
- Access to internet or smart phone
- English speaking
Exclusion Criteria:
- Diagnosis of ASD
- Past year psychiatric hospitalization
There are no exclusion criteria with respect to ethnicity or socioeconomic status.
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación factorial
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Experimental: 3RP treatment
An adapted version of the Relaxation Response Resiliency Program (3RP) for siblings of children with ASD.
The adapted program incorporates the three prongs of the 3RP: RR elicitation, stress awareness, and adaptive strategies.
|
Virtually delivered psycho-educational resiliency training program for teenage siblings of children with ASD.
|
|
Comparador activo: Active Comparator: Waitlist control
An adapted version of the Relaxation Response Resiliency Program (3RP) for siblings of children with ASD.
The adapted program incorporates the three prongs of the 3RP: RR elicitation, stress awareness, and adaptive strategies.
|
Virtually delivered psycho-educational resiliency training program for teenage siblings of children with ASD.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Feasibility assessed by the number participants enrolled.
Periodo de tiempo: 6 months
|
We will assess study feasibility based on number of participants enrolled in the study (target N=40)
|
6 months
|
|
Feasibility assessed by the number SibChat-3RP of sessions attended
Periodo de tiempo: 8 weeks
|
Whether youth attended at least 5 out of 8 total program sessions.
|
8 weeks
|
|
Feasibility assessed by the survey retention post intervention.
Periodo de tiempo: 6 months
|
Among participants randomized to both conditions, feasibility is assessed by the number of participants who completed the T2 and T3 surveys, 3 months and 6 months post baseline, respectively.
|
6 months
|
|
Acceptability assessed using the participant feedback survey
Periodo de tiempo: 3 months
|
The participant feedback survey is a questionnaire made up of likert scales and open ended questions designed to record acceptability of the SibChat-3RP program on topics including length of sessions, number of sessions, and virtual delivery.
|
3 months
|
|
Acceptability assessed by relaxation response adherence
Periodo de tiempo: 3 months
|
Among participants randomized to both conditions, relaxation response adherence is measured at T1, T2 and T3.
Relaxation response adherence is a 1-item likert scale that indicates how often participants practice relaxation response exercises.
Acceptability is determined based on whether participants indicate that they practice relaxation response exercises at least bimonthly 3 months post intervention.
|
3 months
|
|
Effectiveness of trial on improving stress coping ability (assessed using Measure of Current Status-A)
Periodo de tiempo: 3 months
|
Measure of Current Status-A is a questionnaire - the score on the questionnaire is used to indicate stress coping ability.
A change in score indicates a change in indicated stress coping ability.
Comparison of intervention and wait list control 3 months after baseline (T1).
|
3 months
|
|
Effectiveness of trial on improving resiliency (assessed using Current Experiences Scale)
Periodo de tiempo: 3 months
|
Current experiences Scale is a questionnaire.
Improved resiliency is measured base upon change in questionnaire score.
Comparison of intervention and wait list control 3 months after baseline (T1).
|
3 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Pre-post intervention changes as measured by change in primary outcome scores of resiliency and stress coping.
Periodo de tiempo: 3 months
|
Among participants randomized to both conditions, pre-post intervention changes in primary outcome scores of resiliency and stress coping will be assessed using the scores from the questionnaire (includes all primary outcome scores indicated above).
|
3 months
|
|
Sustained improvements in primary outcomes of resiliency and stress coping as measured by sustained change in primary outcome scores.
Periodo de tiempo: 3 months
|
Among immediate condition group only, assess whether end-of-treatment (3 mo.
post enrollment) improvements in primary outcome scores (resiliency and stress coping indicated above; collected using a questionnaire) will be sustained at 6-mo.
post enrollment.
|
3 months
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Karen A Kuhlthau, PhD, Massachusetts General Hospital
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio (Actual)
28 de enero de 2020
Finalización primaria (Actual)
1 de enero de 2021
Finalización del estudio (Actual)
1 de enero de 2021
Fechas de registro del estudio
Enviado por primera vez
20 de febrero de 2020
Primero enviado que cumplió con los criterios de control de calidad
27 de abril de 2020
Publicado por primera vez (Actual)
30 de abril de 2020
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
5 de abril de 2022
Última actualización enviada que cumplió con los criterios de control de calidad
4 de abril de 2022
Última verificación
1 de abril de 2022
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 2019P003218
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
No
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
No
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
No
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .